ME01908B - Novi antagonisti ccr2 receptora i njihova primjena - Google Patents

Novi antagonisti ccr2 receptora i njihova primjena

Info

Publication number: ME01908B
Authority: ME; Montenegro
Prior art keywords: ingelheim; rhein; receptor antagonists; gmbh; ccr2 receptor
Prior art date: 2009-12-17

Application number

MEP-2014-106A

Other languages

English (en)

Inventor

Heiner Ebel

Sara Frattini

Kai Gerlach

Riccardo Giovannini

Christoph Hoenke

Rocco Mazzaferro

Marco Santagostino

Stefan Scheuerer

Christofer Tautermann

Thomas Trieselmann

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-17

Filing date

2010-12-13

Publication date

2014-12-20

2010-12-13 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2014-12-20 Publication of ME01908B publication Critical patent/ME01908B/me

Links

102000004497 CCR2 Receptors Human genes 0.000 title description 2
108010017312 CCR2 Receptors Proteins 0.000 title description 2
239000002464 receptor antagonist Substances 0.000 title description 2
229940044551 receptor antagonist Drugs 0.000 title description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

Description

"(12) PATENTNI SPIS 1 me B 01908 ME (11) ME 01908B (19) Crna Gora (21) Broj prijave: P-2014-106 (22) Datum podnošenja prijave: 13. 12. 2010 (45) Datum objavljivanja patenta: 20. 12. 2014 Glasnik : 16/2014 (51) Me dunarodna klasifikacija MKP C07D491/107 2006.01 C07D405/14 2006.01 A61K31/506 2006.01 A61P29/00 2006.01 (30) Me dunarodno pravo prvenstva / EP / 20090179555 17. 12. 2009 / EP / 20100162621 12. 05. 2010 (96) Broj i datum prijave evropskog patenta: / 10796336.5 13. 12. 2010 (86) Broj i datum me dunarodne prijave: / PCT/EP2010/069549 13. 12. 2010 (73) Nosilac Patenta , Boehringer Ingelheim International GmbH , Binger Strasse 173 , 55216 Ingelheim am Rhein , DE (74) Zastupnik: , RADULOVI C, S. Božidar , Studentska bb, Lamela 3/18 , 81000 Podgorica , ME (72) Pronalaza c , EBEL, Heiner , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , FRATTINI, Sara , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , GERLACH, Kai , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , GIOVANNINI, Riccardo , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , HOENKE, Christoph , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , MAZZAFERRO, Rocco , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , SANTAGOSTINO, Marco , BOEHRINGER INGELHEIM GMBH, Corporate Patent, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , SCHEUERER, Stefan , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , TAUTERMANN, Christofer , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE , TRIESELMANN, Thomas , BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173 , 55216 Ingelheim am Rhein , DE (54) Naziv: me NOVI ANTAGONISTI CCR2 RECEPTORA I NJIHOVA PRIMJENA en NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF"

MEP-2014-106A 2009-12-17 2010-12-13 Novi antagonisti ccr2 receptora i njihova primjena ME01908B (me)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP09179555		2009-12-17
EP10162621		2010-05-12
PCT/EP2010/069549 WO2011073154A1 (en)	2009-12-17	2010-12-13	New ccr2 receptor antagonists and uses thereof
EP10796336.5A EP2513093B1 (en)	2009-12-17	2010-12-13	New ccr2 receptor antagonists and uses thereof

Publications (1)

Publication Number	Publication Date
ME01908B true ME01908B (me)	2014-12-20

Family

ID=43533115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2014-106A ME01908B (me)	2009-12-17	2010-12-13	Novi antagonisti ccr2 receptora i njihova primjena

Country Status (36)

Country	Link
US (6)	US8765949B2 (me)
EP (3)	EP3091012B1 (me)
JP (1)	JP5632014B2 (me)
KR (1)	KR101530234B1 (me)
CN (1)	CN102933579B (me)
AP (1)	AP3170A (me)
AR (1)	AR079636A1 (me)
AU (1)	AU2010332969B2 (me)
BR (1)	BR112012015873B1 (me)
CA (1)	CA2782464C (me)
CL (1)	CL2012001311A1 (me)
CO (1)	CO6650336A2 (me)
CY (1)	CY1115873T1 (me)
DK (1)	DK2513093T3 (me)
EA (1)	EA024397B1 (me)
EC (1)	ECSP12012010A (me)
ES (2)	ES2674275T3 (me)
GE (1)	GEP20146124B (me)
HR (1)	HRP20141143T1 (me)
IL (1)	IL219421A (me)
MA (1)	MA33818B1 (me)
ME (1)	ME01908B (me)
MX (2)	MX2012006964A (me)
MY (1)	MY160471A (me)
NZ (1)	NZ599770A (me)
PE (1)	PE20121614A1 (me)
PH (1)	PH12012501215A1 (me)
PL (2)	PL3091012T3 (me)
PT (2)	PT3091012T (me)
RS (1)	RS53555B1 (me)
SG (1)	SG181722A1 (me)
SI (1)	SI2513093T1 (me)
TN (1)	TN2012000300A1 (me)
TW (1)	TWI473800B (me)
UY (1)	UY33109A (me)
WO (1)	WO2011073154A1 (me)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008145681A2 (en)	2007-05-31	2008-12-04	Boehringer Ingelheim International Gmbh	Ccr2 receptor antagonists and uses thereof
DK2379525T3 (en)	2008-12-19	2015-10-19	Boehringer Ingelheim Int	Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
WO2011073154A1 (en)	2009-12-17	2011-06-23	Boehringer Ingelheim International Gmbh	New ccr2 receptor antagonists and uses thereof
US8877745B2 (en)	2010-05-12	2014-11-04	Boehringer Ingelheim International Gmbh	CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569295B1 (en)	2010-05-12	2014-11-19	Boehringer Ingelheim International GmbH	New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en)	2010-05-17	2014-09-23	Boehringer Ingelheim International Gmbh	CCR2 antagonists and uses thereof
US9018212B2 (en)	2010-05-25	2015-04-28	Boehringer Ingelheim International Gmbh	Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (en)	2010-06-01	2015-10-28	Boehringer Ingelheim International GmbH	New CCR2 antagonists
WO2012171863A1 (en) *	2011-06-16	2012-12-20	Boehringer Ingelheim International Gmbh	New selective ccr2 antagonists
JP5786258B2 (ja) *	2011-07-15	2015-09-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規かつ選択的なｃｃｒ２拮抗薬
EP2771484A1 (en)	2011-10-28	2014-09-03	Galderma Research & Development	New leukocyte infiltrate markers for rosacea and uses thereof
US8877185B2 (en)	2012-05-10	2014-11-04	Stan S. Sastry	Managing and treating keloids
WO2016081801A1 (en) *	2014-11-21	2016-05-26	Millennium Pharmaceuticals, Inc.	Use of an anti-ccr2 antagonist in the treatment of an infectious disease
PT3297438T (pt)	2015-05-21	2022-01-25	Chemocentryx Inc	Moduladores de ccr2
WO2017004537A1 (en)	2015-07-02	2017-01-05	Centrexion Therapeutics Corporation	(4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
CN109475537A (zh) *	2016-06-03	2019-03-15	坎莫森特里克斯公司	治疗肝纤维化的方法
KR20190017913A (ko) *	2016-06-13	2019-02-20	케모센트릭스, 인크.	췌장 암을 치료하는 방법
US10195188B2 (en)	2016-06-13	2019-02-05	Chemocentryx, Inc.	Method of treating pancreatic cancer
CN108017599B (zh) *	2016-11-04	2020-03-03	上海爱科百发生物医药技术有限公司	[3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法
EP4134080B1 (en)	2016-11-23	2024-11-13	ChemoCentryx, Inc.	Ccr2 inhibitors for use in treating renal diseases
US20200087390A1 (en)	2016-12-21	2020-03-19	Amgen Inc.	Anti-tnf alpha antibody formulations
MA50665A (fr)	2017-09-25	2020-08-05	Chemocentryx Inc	Polythérapie utilisant un antagoniste du récepteur 2 de la chimiokine (ccr2) et un inhibiteur pd-1/pd-l1
US10758540B2 (en)	2017-10-11	2020-09-01	Chemocentryx, Inc.	Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
IL275898B2 (en)	2018-01-08	2025-05-01	Chemocentryx Inc	Methods for treating solid tumors with CCR2 antagonists
US20190269664A1 (en)	2018-01-08	2019-09-05	Chemocentryx, Inc.	Methods of treating solid tumors with ccr2 antagonists
US20210322412A1 (en) *	2020-04-20	2021-10-21	Centrexion Therapeutics Corporation	Methods and compositions for treating a coronavirus infection
NL2026714B1 (en) *	2020-10-20	2022-06-16	Lumicks Ca Holding B V	Improved detection of lymphocyte - target cell interaction

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US568885A (en) *		1896-10-06		Can-seaming mechanism
US213428A (en) *		1879-03-18		Improvement in harrow-teeth
US4032526A (en)	1975-10-02	1977-06-28	American Cyanamid Company	1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
GB2068961B (en)	1980-02-13	1983-11-30	Sankyo Co	Quinazoline derivatives
DE3517617A1 (de)	1985-05-15	1986-11-20	Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München	Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
JPS6319745Y2 (me)	1985-11-07	1988-06-01
JPS61165445A (ja)	1986-01-08	1986-07-26	株式会社巴組鐵工所	振動を減少しうる床構造
US5096916A (en)	1990-05-07	1992-03-17	Aegis Technology, Inc.	Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
JPH08502508A (ja)	1992-10-23	1996-03-19	メルクシヤープエンドドームリミテツド	ドーパミンレセプターサブタイプリガンド
JP3166376B2 (ja)	1993-02-03	2001-05-14	松下電器産業株式会社	熱利用装置
US5629235A (en)	1995-07-05	1997-05-13	Winbond Electronics Corporation	Method for forming damage-free buried contact
TW531537B (en)	1995-12-27	2003-05-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5629325A (en)	1996-06-06	1997-05-13	Abbott Laboratories	3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en)	1996-06-06	2002-08-20	Abbott Laboratories	3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6979686B1 (en)	2001-12-07	2005-12-27	Pharmacia Corporation	Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en)	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
AU744539B2 (en)	1997-10-27	2002-02-28	Neurosearch A/S	Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
CA2350081A1 (en)	1998-11-20	2000-06-02	G.D. Searle & Co.	Process for making 5-substituted pyrazoles using dithietanes
US6248755B1 (en)	1999-04-06	2001-06-19	Merck & Co., Inc.	Pyrrolidine modulators of chemokine receptor activity
TR200103214T2 (tr)	1999-05-04	2002-03-21	Schering Corporation	CCR5 antagonistleri olarak yararlì piperazin trevleri.
GB0004153D0 (en)	2000-02-23	2000-04-12	Astrazeneca Uk Ltd	Novel use
US20020045613A1 (en)	2000-04-27	2002-04-18	Heinz Pauls	1-aroyl-piperidinyl benzamidines
OA12274A (en)	2000-05-22	2006-05-09	Aventis Pharma Inc	Arylmethylamine derivatives for use as tryptase inhibitors.
DE50103666D1 (de)	2000-10-12	2004-10-21	Boehringer Ingelheim Pharma	Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
AR035700A1 (es)	2001-05-08	2004-06-23	Astrazeneca Ab	Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
PL208137B1 (pl)	2001-06-22	2011-03-31	Boehringer Ingelheim Pharma	Bezwodny krystaliczny bromek tiotropium, sposób jego wytwarzania i zastosowanie krystalicznego monohydratu bromku tiotropium do wytwarzania krystalicznego bezwodnego bromku tiotropium
AU2002363236A1 (en)	2001-10-30	2003-05-12	Millennium Pharmaceuticals, Inc.	Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en)	2001-12-17	2004-10-19	Sunesis Pharmaceuticals, Inc.	Small-molecule inhibitors of interleukin-2
AU2003203148A1 (en)	2002-02-05	2003-09-02	High Point Pharmaceuticals, Llc	Novel aryl- and heteroarylpiperazines
JP2003240776A (ja)	2002-02-13	2003-08-27	Horiba Ltd	クロマトグラフリーダを用いる測定方法およびそれに用いる試験片ホルダ並びにクロマトグラフリーダを用いる検査／測定装置
HUP0200849A2 (hu)	2002-03-06	2004-08-30	Sanofi-Synthelabo	N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US20030195192A1 (en)	2002-04-05	2003-10-16	Fortuna Haviv	Nicotinamides having antiangiogenic activity
ATE395343T1 (de)	2002-03-13	2008-05-15	Janssen Pharmaceutica Nv	Sulfonylderivate als histone-deacetylase- inhibitoren
US20040014744A1 (en)	2002-04-05	2004-01-22	Fortuna Haviv	Substituted pyridines having antiangiogenic activity
CA2483253A1 (en)	2002-04-24	2003-11-06	Takeda Pharmaceutical Company Limited	Use of compounds having ccr antagonism
CA2483752C (en)	2002-04-29	2011-03-29	Merck & Co., Inc.	Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2003104223A1 (en)	2002-06-05	2003-12-18	Pharmacia Corporation	Pyrazole-derivatives as p38 kinase inhibitors
AU2003270199A1 (en)	2002-09-13	2004-04-30	Glaxo Group Limited	Urea compounds active as vanilloid receptor antagonists for the treatment of pain
SE0203304D0 (sv)	2002-11-07	2002-11-07	Astrazeneca Ab	Novel Coumpounds
GB0229618D0 (en)	2002-12-19	2003-01-22	Cancer Rec Tech Ltd	Pyrazole compounds
US20040147561A1 (en)	2002-12-27	2004-07-29	Wenge Zhong	Pyrid-2-one derivatives and methods of use
WO2004074438A2 (en) *	2003-02-14	2004-09-02	Smithkline Beecham Corporation	Ccr8 antagonists
AU2004220321B2 (en)	2003-03-12	2010-02-25	Kudos Pharmaceuticals Ltd	Phthalazinone derivatives
MXPA05011352A (es)	2003-04-23	2005-11-28	Glaxo Group Ltd	Derivados de piperazina y su uso para el tratamiento de enfermedades neurologicas y psiquiatricas.
FR2854158B1 (fr)	2003-04-25	2006-11-17	Sanofi Synthelabo	Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
WO2005014571A1 (en)	2003-07-18	2005-02-17	Glaxo Group Limited	Substituted piperidines as histamine h3 receptor ligands
CA2532236C (en)	2003-07-29	2011-08-23	Novo Nordisk A/S	Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
BRPI0417605B8 (pt)	2003-12-18	2021-05-25	Incyte Corp	n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende.
GB0403155D0 (en)	2004-02-12	2004-03-17	Vernalis Res Ltd	Chemical compounds
CN1950082B (zh)	2004-03-03	2013-02-06	凯莫森特里克斯股份有限公司	双环和桥连的含氮杂环化物
PE20060285A1 (es)	2004-03-30	2006-05-08	Aventis Pharma Inc	Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
CN1972914A (zh)	2004-03-31	2007-05-30	詹森药业有限公司	作为组胺h3受体配合体的非咪唑杂环化合物
WO2005117909A2 (en)	2004-04-23	2005-12-15	Exelixis, Inc.	Kinase modulators and methods of use
US20100234409A1 (en)	2004-05-21	2010-09-16	Lihu Yang	Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
WO2005118588A1 (ja)	2004-06-02	2005-12-15	Takeda Pharmaceutical Company Limited	縮合複素環化合物
FR2871157A1 (fr)	2004-06-04	2005-12-09	Aventis Pharma Sa	Produits biaryl aromatiques, compositions les contenant et utilisation
EA200700117A1 (ru)	2004-06-24	2007-06-29	Инсайт Корпорейшн	N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
AU2005267385B2 (en)	2004-06-25	2011-11-10	Janssen Pharmaceutica N.V.	Quaternary salt CCR2 antagonists
EP1763347A4 (en) *	2004-06-28	2009-05-20	Incyte Corp	3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS
CN1976702A (zh) *	2004-06-28	2007-06-06	因赛特公司	作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类
EP1791827A1 (en)	2004-08-26	2007-06-06	Kudos Pharmaceuticals Limited	4-heteroarylmethyl substituted phthalazinone derivatives
GB0420831D0 (en)	2004-09-17	2004-10-20	Glaxo Group Ltd	Novel compounds
JP4958786B2 (ja)	2004-09-20	2012-06-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	複素環誘導体および治療薬としてのそれらの使用
GB0421525D0 (en)	2004-09-28	2004-10-27	Novartis Ag	Inhibitors of protein kineses
WO2006038734A1 (en)	2004-10-08	2006-04-13	Astellas Pharma Inc.	Pyridazinone derivatives cytokines inhibitors
EP1812408B1 (en)	2004-11-02	2013-10-09	Northwestern University	Pyridazine compounds, compositions and methods
PA8653301A1 (es)	2004-11-22	2006-11-09	Incyte Corp Incyte Corp	Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
DE102004061751A1 (de)	2004-12-22	2006-07-06	Bayer Healthcare Ag	Cyanoguanidin-substituierte Pyrazoline
MX2007010076A (es)	2005-02-17	2007-10-16	Astellas Pharma Inc	Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
EP2527337A1 (en)	2005-04-14	2012-11-28	Bristol-Myers Squibb Company	Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
JP2008537953A (ja)	2005-04-15	2008-10-02	エランファーマシューティカルズ，インコーポレイテッド	ブラジキニンｂ１受容体拮抗作用に有用な新規化合物
AR053712A1 (es)	2005-04-18	2007-05-16	Neurogen Corp	Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
KR20080016659A (ko)	2005-05-20	2008-02-21	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제의 억제제로서 유용한 피롤로피리딘
EP2386554A1 (en)	2005-07-04	2011-11-16	High Point Pharmaceuticals, LLC	Compounds active at the histamine H3 receptor
AU2006275568A1 (en)	2005-08-02	2007-02-08	Neurogen Corporation	Dipiperazinyl ketones and related analogues
GB0517184D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
AR055203A1 (es)	2005-08-31	2007-08-08	Otsuka Pharma Co Ltd	Derivados de benzotiofeno con propiedades antipsicoticas
TW200800999A (en) *	2005-09-06	2008-01-01	Astrazeneca Ab	Novel compounds
JP5335426B2 (ja)	2005-09-27	2013-11-06	アイアールエム・リミテッド・ライアビリティ・カンパニー	ジアリールアミン含有化合物および組成物、ならびにｃ−ｋｉｔ受容体のモジュレーターとしてのそれらの使用
JO2769B1 (en)	2005-10-26	2014-03-15	جانسين فارماسوتيكا ان. في	Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007053495A2 (en)	2005-11-01	2007-05-10	Millennium Pharmaceuticals, Inc.	Compounds useful as antagonists of ccr2
US8067457B2 (en)	2005-11-01	2011-11-29	Millennium Pharmaceuticals, Inc.	Compounds useful as antagonists of CCR2
WO2007092065A2 (en)	2005-11-14	2007-08-16	Irm Llc	Compounds and compositions as lxr modulators
US20090182140A1 (en) *	2005-12-02	2009-07-16	Mitsubishi Tanabe Pharma Corporation	Alicyclic Heterocyclic Compound
AR058554A1 (es)	2005-12-20	2008-02-13	Novartis Ag	Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
IL172838A (en)	2005-12-27	2010-06-16	Joma Int As	Methods for production of metal oxide nano particles with controlled properties and nano particles and preparations produced thereby
WO2007084868A2 (en)	2006-01-17	2007-07-26	Kalypsys, Inc.	Treatment of disorders by activation of the unfolded protein response
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
JP5503874B2 (ja)	2006-02-28	2014-05-28	ダートニューロサイエンス（ケイマン）エルティーディー	治療化合物
CA2643066A1 (en)	2006-03-16	2007-09-20	Pfizer Products Inc.	Pyrazole compounds
EP2013174B1 (en)	2006-04-11	2013-05-08	Merck Sharp & Dohme Corp.	Diaryl substituted alkanes
US7807671B2 (en)	2006-04-25	2010-10-05	Bristol-Myers Squibb Company	Diketo-piperazine and piperidine derivatives as antiviral agents
WO2007127448A2 (en)	2006-04-28	2007-11-08	Northwestern University	Salts of pyridazine compounds
US20080039450A1 (en)	2006-06-22	2008-02-14	Jensen Annika J	Compounds
JP5448164B2 (ja)	2006-07-28	2014-03-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を変調する化合物
GB0617575D0 (en)	2006-09-06	2006-10-18	Syngenta Ltd	Herbicidal compounds and compositions
JP5030114B2 (ja)	2006-09-25	2012-09-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体をモジュレートする化合物
CN101534824A (zh)	2006-11-17	2009-09-16	艾博特公司	作为化学活素受体拮抗剂的氨基吡咯烷
PT2698062E (pt)	2006-12-28	2015-10-19	Abbvie Inc	Inibidores da poli (adp-ribose) polimerase
EP2121633A2 (en)	2007-02-12	2009-11-25	Merck & Co., Inc.	Piperazine derivatives for treatment of ad and related conditions
JP4785881B2 (ja)	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
FR2915552B1 (fr)	2007-04-27	2009-11-06	Technip France	Conduite tubulaire flexible pour le transport d'hydrocarbures gazeux.
WO2008145681A2 (en)	2007-05-31	2008-12-04	Boehringer Ingelheim International Gmbh	Ccr2 receptor antagonists and uses thereof
CA2691662A1 (en)	2007-07-02	2009-01-08	F. Hoffmann-La Roche Ag	Imidazole derivatives as ccr2 receptor antagonists
US7977358B2 (en)	2007-07-26	2011-07-12	Hoffmann-La Roche Inc.	Pyrazol derivatives
WO2009026204A1 (en)	2007-08-22	2009-02-26	Irm Llc	2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
MX2010003621A (es)	2007-10-01	2010-04-14	Hoffmann La Roche	N-heterociclil biaril carboxamidas como antagonistas del receptor ccr.
CA2701932C (en)	2007-10-09	2015-10-20	F. Hoffmann-La Roche Ag	Chiral cis-imidazolines
US20100218349A1 (en)	2007-10-12	2010-09-02	Whang Jong O	Tying tool for shoelace
US20090131417A1 (en)	2007-11-20	2009-05-21	Letavic Michael A	Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
WO2009066084A1 (en)	2007-11-21	2009-05-28	F. Hoffmann-La Roche Ag	2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
EP2062889A1 (de)	2007-11-22	2009-05-27	Boehringer Ingelheim Pharma GmbH & Co. KG	Verbindungen
CA2705405A1 (en)	2007-11-22	2009-05-28	Boehringer Ingelheim International Gmbh	New compounds
AU2009259496A1 (en)	2008-06-18	2009-12-23	F. Hoffmann-La Roche Ag	Novel heteroaryl carboxamide derivatives
NZ601483A (en)	2008-08-04	2013-10-25	Chdi Foundation Inc	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB0815369D0 (en)	2008-08-22	2008-10-01	Summit Corp Plc	Compounds for treatment of duchenne muscular dystrophy
EP2331506B1 (de)	2008-09-02	2013-07-03	Boehringer Ingelheim International GmbH	Neue benzamide, deren herstellung und deren verwendung als arzneimittel
US8048899B2 (en)	2008-09-25	2011-11-01	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
DK2379525T3 (en) *	2008-12-19	2015-10-19	Boehringer Ingelheim Int	Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
JP2012518603A (ja)	2009-02-23	2012-08-16	メルクカナダインコーポレイテッド	ステアロイル−コエンザイムａデルタ−９デサチュラーゼの阻害剤としての複素環誘導体
WO2011073154A1 (en)	2009-12-17	2011-06-23	Boehringer Ingelheim International Gmbh	New ccr2 receptor antagonists and uses thereof
WO2011073155A1 (en)	2009-12-17	2011-06-23	Boehringer Ingelheim International Gmbh	Novel antagonists for ccr2 and uses thereof
US8329735B2 (en)	2010-03-05	2012-12-11	Boehringer Ingelheim International Gmbh	Tetrazole compounds which selectively modulate the CB2 receptor
EP2569295B1 (en)	2010-05-12	2014-11-19	Boehringer Ingelheim International GmbH	New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8877745B2 (en)	2010-05-12	2014-11-04	Boehringer Ingelheim International Gmbh	CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en)	2010-05-17	2014-09-23	Boehringer Ingelheim International Gmbh	CCR2 antagonists and uses thereof
US9018212B2 (en)	2010-05-25	2015-04-28	Boehringer Ingelheim International Gmbh	Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (en)	2010-06-01	2015-10-28	Boehringer Ingelheim International GmbH	New CCR2 antagonists
WO2012171863A1 (en)	2011-06-16	2012-12-20	Boehringer Ingelheim International Gmbh	New selective ccr2 antagonists
JP5786258B2 (ja)	2011-07-15	2015-09-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規かつ選択的なｃｃｒ２拮抗薬
JP6229575B2 (ja)	2014-03-31	2017-11-15	京セラドキュメントソリューションズ株式会社	画像処理装置
WO2017004537A1 (en) *	2015-07-02	2017-01-05	Centrexion Therapeutics Corporation	(4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate

2010
- 2010-12-13 WO PCT/EP2010/069549 patent/WO2011073154A1/en not_active Ceased
- 2010-12-13 ES ES16157027.0T patent/ES2674275T3/es active Active
- 2010-12-13 AU AU2010332969A patent/AU2010332969B2/en active Active
- 2010-12-13 PE PE2012000827A patent/PE20121614A1/es active IP Right Grant
- 2010-12-13 PT PT161570270T patent/PT3091012T/pt unknown
- 2010-12-13 JP JP2012543667A patent/JP5632014B2/ja active Active
- 2010-12-13 BR BR112012015873-2A patent/BR112012015873B1/pt not_active IP Right Cessation
- 2010-12-13 ME MEP-2014-106A patent/ME01908B/me unknown
- 2010-12-13 MX MX2012006964A patent/MX2012006964A/es active IP Right Grant
- 2010-12-13 PH PH1/2012/501215A patent/PH12012501215A1/en unknown
- 2010-12-13 ES ES10796336.5T patent/ES2524829T3/es active Active
- 2010-12-13 RS RS20140526A patent/RS53555B1/sr unknown
- 2010-12-13 PL PL16157027T patent/PL3091012T3/pl unknown
- 2010-12-13 KR KR1020127014412A patent/KR101530234B1/ko not_active Expired - Fee Related
- 2010-12-13 PT PT107963365T patent/PT2513093E/pt unknown
- 2010-12-13 PL PL10796336T patent/PL2513093T3/pl unknown
- 2010-12-13 AP AP2012006276A patent/AP3170A/xx active
- 2010-12-13 EA EA201200876A patent/EA024397B1/ru not_active IP Right Cessation
- 2010-12-13 DK DK10796336.5T patent/DK2513093T3/da active
- 2010-12-13 SI SI201030770T patent/SI2513093T1/sl unknown
- 2010-12-13 CN CN201080057415.2A patent/CN102933579B/zh active Active
- 2010-12-13 MY MYPI2012002736A patent/MY160471A/en unknown
- 2010-12-13 HR HRP20141143AT patent/HRP20141143T1/hr unknown
- 2010-12-13 EP EP16157027.0A patent/EP3091012B1/en active Active
- 2010-12-13 SG SG2012044129A patent/SG181722A1/en unknown
- 2010-12-13 CA CA2782464A patent/CA2782464C/en active Active
- 2010-12-13 NZ NZ599770A patent/NZ599770A/en not_active IP Right Cessation
- 2010-12-13 EP EP14177921.5A patent/EP2813503B1/en not_active Not-in-force
- 2010-12-13 EP EP10796336.5A patent/EP2513093B1/en active Active
- 2010-12-13 GE GEAP201012789A patent/GEP20146124B/en unknown
- 2010-12-13 MX MX2013008863A patent/MX346393B/es unknown
- 2010-12-16 UY UY33109A patent/UY33109A/es not_active Application Discontinuation
- 2010-12-16 AR ARP100104699A patent/AR079636A1/es not_active Application Discontinuation
- 2010-12-16 US US12/969,745 patent/US8765949B2/en active Active
- 2010-12-16 TW TW99144272A patent/TWI473800B/zh not_active IP Right Cessation
2012
- 2012-04-25 IL IL219421A patent/IL219421A/en active IP Right Grant
- 2012-05-18 CL CL2012001311A patent/CL2012001311A1/es unknown
- 2012-06-13 TN TNP2012000300A patent/TN2012000300A1/en unknown
- 2012-06-14 MA MA34961A patent/MA33818B1/fr unknown
- 2012-06-15 CO CO12101565A patent/CO6650336A2/es active IP Right Grant
- 2012-06-28 EC ECSP12012010 patent/ECSP12012010A/es unknown
2014
- 2014-04-24 US US14/260,552 patent/US9670222B2/en active Active
- 2014-11-12 CY CY20141100939T patent/CY1115873T1/el unknown
2017
- 2017-05-26 US US15/606,749 patent/US10196402B2/en active Active
2018
- 2018-12-27 US US16/233,315 patent/US11046706B2/en active Active
2021
- 2021-06-11 US US17/345,110 patent/US11731981B2/en active Active
2023
- 2023-07-31 US US18/362,028 patent/US12209094B2/en active Active

Also Published As

Publication number	Publication date
PT3091012T (pt)	2018-06-27
US8765949B2 (en)	2014-07-01
AP2012006276A0 (en)	2012-06-30
PT2513093E (pt)	2014-10-22
PL2513093T3 (pl)	2015-03-31
SI2513093T1 (sl)	2014-11-28
ES2674275T3 (es)	2018-06-28
HRP20141143T1 (hr)	2015-01-02
RS53555B1 (sr)	2015-02-27
AU2010332969B2 (en)	2015-02-12
JP5632014B2 (ja)	2014-11-26
US20170362249A1 (en)	2017-12-21
ES2524829T3 (es)	2014-12-12
PL3091012T3 (pl)	2018-08-31
TW201130816A (en)	2011-09-16
US11731981B2 (en)	2023-08-22
US12209094B2 (en)	2025-01-28
IL219421A0 (en)	2012-06-28
MA33818B1 (fr)	2012-12-03
US9670222B2 (en)	2017-06-06
US20190300541A1 (en)	2019-10-03
CO6650336A2 (es)	2013-04-15
CL2012001311A1 (es)	2012-10-12
MX2012006964A (es)	2012-07-17
KR20120123652A (ko)	2012-11-09
EP2813503A1 (en)	2014-12-17
EP2813503B1 (en)	2016-04-20
CN102933579A (zh)	2013-02-13
CN102933579B (zh)	2015-07-15
SG181722A1 (en)	2012-07-30
KR101530234B1 (ko)	2015-06-19
MY160471A (en)	2017-03-15
CY1115873T1 (el)	2017-01-25
AR079636A1 (es)	2012-02-08
EP2513093A1 (en)	2012-10-24
US20220002310A1 (en)	2022-01-06
AP3170A (en)	2015-03-31
US20240109909A1 (en)	2024-04-04
DK2513093T3 (da)	2014-09-29
EP2513093B1 (en)	2014-08-27
NZ599770A (en)	2014-06-27
PE20121614A1 (es)	2012-12-21
BR112012015873A2 (pt)	2019-09-24
EA201200876A1 (ru)	2013-01-30
EP3091012A1 (en)	2016-11-09
EP3091012B1 (en)	2018-04-11
ECSP12012010A (es)	2012-08-31
AU2010332969A1 (en)	2012-05-31
PH12012501215A1 (en)	2015-11-13
CA2782464A1 (en)	2011-06-23
WO2011073154A1 (en)	2011-06-23
TN2012000300A1 (en)	2013-12-12
US20120004252A1 (en)	2012-01-05
TWI473800B (zh)	2015-02-21
GEP20146124B (en)	2014-07-25
UY33109A (es)	2011-07-29
EA024397B1 (ru)	2016-09-30
JP2013514301A (ja)	2013-04-25
IL219421A (en)	2015-07-30
US20140235661A1 (en)	2014-08-21
HK1178147A1 (en)	2013-09-06
MX346393B (es)	2017-03-17
US11046706B2 (en)	2021-06-29
CA2782464C (en)	2016-11-29
BR112012015873B1 (pt)	2021-06-01
US10196402B2 (en)	2019-02-05

Publication	Publication Date	Title
BRPI0918492A2 (pt)	2015-12-01	uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
PT2547679E (pt)	2016-01-27	Derivados de 2,3-di-hidro-1h-indeno-1-il-2,7-diazaspiro[3.6]nonano e sua utilização como antagonistas ou agonistas inversos do receptor de grelina
BRPI0813225A2 (pt)	2014-12-23	Catalisador de craqueamento catalítico e preparação e uso do mesmo.
BRPI1011346A2 (pt)	2016-10-18	partícula de polímero, composição tensoativa, processos de formação de partículas de polímero, e, uso das mesmas
EP2423233A4 (en)	2012-09-26	BY IN VIVO RELEASE STABILIZED FUSION PROTEIN WITH INCREASED IN VIVO HALF TIME, AND PROCEDURE TO INCREASE IN VIVO HALF TIME
BR112013009145A2 (pt)	2016-07-26	"mantas de não tecido, pano de limpeza e métodos para fabricsção de uma manta"
HRP20181727T1 (hr)	2019-02-08	Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
BRPI0806589A2 (pt)	2014-05-13	Catalisador, sua preparação e uso.
BRPI0812575A2 (pt)	2014-09-30	Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, sequência de nucleotídeos
FI20045503L (fi)	2006-06-29	Anturijärjestelmä, asuste ja sykemittari
BRPI0810872A2 (pt)	2014-10-29	Processos para a cristalização de um composto, e para a produção de partículas escoáveis ou desepjáveis de um composto, particula escoável ou despejável de um composto, e, uso das partículas escoáveis ou despejáveis de um composto.
FR2915199B1 (fr)	2010-01-22	Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
IL215603A0 (en)	2011-12-29	Human protein scaffold with controlled serum pharmacokinetics, compositions comprising the same and uses thereof
EP2131654A4 (en)	2011-02-02	Bipyridine-carboxamide-orexin receptor Antagonist
BRPI0912988A2 (pt)	2019-09-24	compostos bicíclicos tendo atividade no receptor cxcr4.
BRPI0814529A2 (pt)	2015-01-27	Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.
BRPI0812766A2 (pt)	2014-12-02	4-cloro-4-alcóxi-1,1,1-triflúor-2-butanonas, preparação das mesmas e uso das mesmas no preparo de 4-alcóxi-1,1,1-triflúor-3-buten-2-onas
BRPI0808025A2 (pt)	2014-06-24	Composto de benzimidazol e uso farmacêutico do mesmo
FR2910473B1 (fr)	2009-02-13	Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
EP2409247A4 (en)	2016-06-01	CLIENT-CENTERED USE CLASSIFICATION
BRPI0810323A2 (pt)	2014-10-14	"combinação de ácido pirrolidona 5-carboxílico, uso do ácido pirrolidona 5-carboxílico, composição e seu uso"
BRPI0911772A2 (pt)	2017-06-27	composto, composição farmacêutica, e, uso do composto.
BRPI0910884A2 (pt)	2015-10-06	composição imunogênica, método para tratar ou prevenir infecção ou doença estafilocócicas, e, uso de uma composição imunogênica.
EP2157096A4 (en)	2010-12-22	AMPHIPATHIC MOLECULAR, MOLECULAR AGGREGATE WITH THE AMPHIPATHIC MOLECULE AND USE OF THE MOLECULAR AGGREGATE
CL2008001795A1 (es)	2008-10-10	Uso de un antagonista par1 en el tratamiento de la fibrilacion atrial.